CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...
UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...
The FDA has issued draft guidance that could speed up approval pathways for rare disease therapies using genome editing technologies. This framework is directly relevant to CRISPR Therapeutics, which ...
A popular gene-editing technique may unintentionally delete and rearrange DNA bases, according to a new study published in Nature Biotechnology. The study involves the use of CRISPR-Cas9, a system ...
CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...
A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...
Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results